GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Retained Earnings

Akeso (AKESF) Retained Earnings : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akeso Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Akeso's retained earnings for the quarter that ended in Dec. 2024 was $0.0 Mil.

Akeso's quarterly retained earnings declined from Dec. 2023 ($-264.8 Mil) to Jun. 2024 ($-293.4 Mil) but then increased from Jun. 2024 ($-293.4 Mil) to Dec. 2024 ($0.0 Mil).

Akeso's annual retained earnings increased from Dec. 2022 ($-561.9 Mil) to Dec. 2023 ($-264.8 Mil) and increased from Dec. 2023 ($-264.8 Mil) to Dec. 2024 ($0.0 Mil).

Akeso Retained Earnings Historical Data

The historical data trend for Akeso's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Retained Earnings Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -256.04 -431.64 -561.94 -264.85 -

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -561.94 - -264.85 -293.37 -

Akeso Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Akeso  (OTCPK:AKESF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Akeso Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Retained Earnings
Comparable Companies
HKSE:01801 HKSE:02269 HKSE:01177 HKSE:06990 HKSE:01877 HKSE:09995 HKSE:01530 HKSE:01548 HKSE:02696 HKSE:09969 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
09926:Hong Kong 4RY:Germany
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Website
https://www.akesobio.com
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.